TrialCancer2025

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.

Michael Cecchini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.